Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

Virginia M. Klimek, Emily K. Dolezal, Michael T. Tees, Sean M. Devlin, Karen Stein, Alejandro Romero, Stephen D. Nimer

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

Original languageEnglish (US)
Pages (from-to)1093-1097
Number of pages5
JournalLeukemia Research
Issue number9
StatePublished - Sep 2012
Externally publishedYes


  • 5-Azacytidine
  • Decitabine
  • Leukemia
  • Therapy-related cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology


Dive into the research topics of 'Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this